InfuSystem Holdings, Inc. (AMEX: INFU) Stock Competitors & Peer Comparison
See INFU's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INFU and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INFU | $9.12 | +2.59% | 183.9M | 23.97 | $0.38 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
INFU vs BDX Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas BDX's P/E ratio is 11.62. In terms of profitability, INFU's ROE is +0.14%, compared to BDX's ROE of +0.05%. Regarding short-term risk, INFU is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
INFU vs BDXA Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas BDXA's P/E ratio is 45.70. In terms of profitability, INFU's ROE is +0.14%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, INFU is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
INFU vs MDLN Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas MDLN's P/E ratio is 45.06. In terms of profitability, INFU's ROE is +0.14%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, INFU is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
INFU vs WST Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas WST's P/E ratio is 41.19. In terms of profitability, INFU's ROE is +0.14%, compared to WST's ROE of +0.19%. Regarding short-term risk, INFU is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for INFU.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
INFU vs HOLX Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas HOLX's P/E ratio is 31.54. In terms of profitability, INFU's ROE is +0.14%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
INFU vs COO Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas COO's P/E ratio is 15.42. In terms of profitability, INFU's ROE is +0.14%, compared to COO's ROE of +0.03%. Regarding short-term risk, INFU is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
INFU vs BDXB Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas BDXB's P/E ratio is 7.60. In terms of profitability, INFU's ROE is +0.14%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, INFU is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
INFU vs BAX Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas BAX's P/E ratio is 10.77. In terms of profitability, INFU's ROE is +0.14%, compared to BAX's ROE of -0.16%. Regarding short-term risk, INFU is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
INFU vs ATR Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ATR's P/E ratio is 23.13. In terms of profitability, INFU's ROE is +0.14%, compared to ATR's ROE of +0.14%. Regarding short-term risk, INFU is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
INFU vs AVTR Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas AVTR's P/E ratio is 13.46. In terms of profitability, INFU's ROE is +0.14%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, INFU is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
INFU vs RGEN Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas RGEN's P/E ratio is 73.31. In terms of profitability, INFU's ROE is +0.14%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, INFU is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
INFU vs TFX Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas TFX's P/E ratio is 12.32. In terms of profitability, INFU's ROE is +0.14%, compared to TFX's ROE of -0.28%. Regarding short-term risk, INFU is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
INFU vs BLCO Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas BLCO's P/E ratio is 24.88. In terms of profitability, INFU's ROE is +0.14%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, INFU is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
INFU vs STVN Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas STVN's P/E ratio is 31.81. In terms of profitability, INFU's ROE is +0.14%, compared to STVN's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
INFU vs MMSI Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas MMSI's P/E ratio is 19.01. In terms of profitability, INFU's ROE is +0.14%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, INFU is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
INFU vs ICUI Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ICUI's P/E ratio is 19.66. In terms of profitability, INFU's ROE is +0.14%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, INFU is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
INFU vs HAE Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas HAE's P/E ratio is 15.86. In terms of profitability, INFU's ROE is +0.14%, compared to HAE's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
INFU vs XRAY Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas XRAY's P/E ratio is 9.04. In terms of profitability, INFU's ROE is +0.14%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, INFU is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for INFU.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
INFU vs LMAT Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas LMAT's P/E ratio is 37.05. In terms of profitability, INFU's ROE is +0.14%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, INFU is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
INFU vs PLSE Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas PLSE's P/E ratio is -27.48. In terms of profitability, INFU's ROE is +0.14%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, INFU is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
INFU vs ATRC Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, INFU's ROE is +0.14%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, INFU is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
INFU vs BLFS Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas BLFS's P/E ratio is -141.85. In terms of profitability, INFU's ROE is +0.14%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, INFU is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
INFU vs AZTA Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas AZTA's P/E ratio is 60.82. In terms of profitability, INFU's ROE is +0.14%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, INFU is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
INFU vs KMTS Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas KMTS's P/E ratio is -8.92. In terms of profitability, INFU's ROE is +0.14%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, INFU is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
INFU vs STAA Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas STAA's P/E ratio is 41.02. In terms of profitability, INFU's ROE is +0.14%, compared to STAA's ROE of -0.06%. Regarding short-term risk, INFU is similarly volatile compared to STAA. This indicates similar risk in terms of short-term price fluctuations for INFU.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
INFU vs QDEL Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas QDEL's P/E ratio is 11.98. In terms of profitability, INFU's ROE is +0.14%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, INFU is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
INFU vs ATRI Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ATRI's P/E ratio is 64.50. In terms of profitability, INFU's ROE is +0.14%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, INFU is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
INFU vs ANGO Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ANGO's P/E ratio is -34.85. In terms of profitability, INFU's ROE is +0.14%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, INFU is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
INFU vs NNNN Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas NNNN's P/E ratio is 145.38. In terms of profitability, INFU's ROE is +0.14%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, INFU is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
INFU vs OSUR Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas OSUR's P/E ratio is -4.78. In terms of profitability, INFU's ROE is +0.14%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, INFU is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
INFU vs SMTI Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas SMTI's P/E ratio is -426.00. In terms of profitability, INFU's ROE is +0.14%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, INFU is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
INFU vs UTMD Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas UTMD's P/E ratio is 19.86. In terms of profitability, INFU's ROE is +0.14%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, INFU is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check UTMD's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
INFU vs KRMD Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas KRMD's P/E ratio is -95.75. In terms of profitability, INFU's ROE is +0.14%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, INFU is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
INFU vs PDEX Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas PDEX's P/E ratio is 19.34. In terms of profitability, INFU's ROE is +0.14%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, INFU is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
INFU vs MBOT Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas MBOT's P/E ratio is -6.58. In terms of profitability, INFU's ROE is +0.14%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, INFU is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
INFU vs AKYA Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas AKYA's P/E ratio is -1.34. In terms of profitability, INFU's ROE is +0.14%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, INFU is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
INFU vs STSS Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas STSS's P/E ratio is -0.02. In terms of profitability, INFU's ROE is +0.14%, compared to STSS's ROE of -1.66%. Regarding short-term risk, INFU is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
INFU vs DXR Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas DXR's P/E ratio is 27.33. In terms of profitability, INFU's ROE is +0.14%, compared to DXR's ROE of +0.22%. Regarding short-term risk, INFU is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
INFU vs OMIC Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas OMIC's P/E ratio is -0.58. In terms of profitability, INFU's ROE is +0.14%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, INFU is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for INFU.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
INFU vs IGAP Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas IGAP's P/E ratio is -10.52. In terms of profitability, INFU's ROE is +0.14%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, INFU is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for INFU.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
INFU vs NEPH Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas NEPH's P/E ratio is 50.86. In terms of profitability, INFU's ROE is +0.14%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, INFU is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
INFU vs MLSS Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas MLSS's P/E ratio is -6.50. In terms of profitability, INFU's ROE is +0.14%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, INFU is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
INFU vs POCI Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas POCI's P/E ratio is -6.07. In terms of profitability, INFU's ROE is +0.14%, compared to POCI's ROE of -0.37%. Regarding short-term risk, INFU is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
INFU vs SDC Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas SDC's P/E ratio is -0.03. In terms of profitability, INFU's ROE is +0.14%, compared to SDC's ROE of -1.96%. Regarding short-term risk, INFU is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
INFU vs HBIO Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas HBIO's P/E ratio is -16.81. In terms of profitability, INFU's ROE is +0.14%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, INFU is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
INFU vs IVC Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas IVC's P/E ratio is -0.79. In terms of profitability, INFU's ROE is +0.14%, compared to IVC's ROE of -0.46%. Regarding short-term risk, INFU is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
INFU vs RVP Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas RVP's P/E ratio is -2.06. In terms of profitability, INFU's ROE is +0.14%, compared to RVP's ROE of -0.08%. Regarding short-term risk, INFU is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for INFU.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
INFU vs ZJYL Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, INFU's ROE is +0.14%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, INFU is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
INFU vs FEMY Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas FEMY's P/E ratio is -10.25. In terms of profitability, INFU's ROE is +0.14%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, INFU is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for INFU.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
INFU vs RGNT Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas RGNT's P/E ratio is -0.08. In terms of profitability, INFU's ROE is +0.14%, compared to RGNT's ROE of N/A. Regarding short-term risk, INFU is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
INFU vs NSTG Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas NSTG's P/E ratio is -0.03. In terms of profitability, INFU's ROE is +0.14%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, INFU is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
INFU vs NXGL Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas NXGL's P/E ratio is -1.13. In terms of profitability, INFU's ROE is +0.14%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, INFU is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
INFU vs POAI Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas POAI's P/E ratio is -0.03. In terms of profitability, INFU's ROE is +0.14%, compared to POAI's ROE of -107.05%. Regarding short-term risk, INFU is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
INFU vs LUCY Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas LUCY's P/E ratio is -0.39. In terms of profitability, INFU's ROE is +0.14%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, INFU is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
INFU vs MHUA Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas MHUA's P/E ratio is 0.25. In terms of profitability, INFU's ROE is +0.14%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, INFU is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
INFU vs NXGLW Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, INFU's ROE is +0.14%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, INFU is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
INFU vs GMVD Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas GMVD's P/E ratio is -0.01. In terms of profitability, INFU's ROE is +0.14%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, INFU is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
INFU vs GMVDW Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas GMVDW's P/E ratio is N/A. In terms of profitability, INFU's ROE is +0.14%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, INFU is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
INFU vs AVGR Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas AVGR's P/E ratio is -0.05. In terms of profitability, INFU's ROE is +0.14%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, INFU is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
INFU vs LUCYW Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, INFU's ROE is +0.14%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, INFU is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
INFU vs GCTK Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas GCTK's P/E ratio is -0.01. In terms of profitability, INFU's ROE is +0.14%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, INFU is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
INFU vs APR Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, APR has a market cap of 0. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas APR's P/E ratio is 22.59. In terms of profitability, INFU's ROE is +0.14%, compared to APR's ROE of +9.81%. Regarding short-term risk, INFU is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
INFU vs IIN Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, IIN has a market cap of 0. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas IIN's P/E ratio is 226.45. In terms of profitability, INFU's ROE is +0.14%, compared to IIN's ROE of -0.00%. Regarding short-term risk, INFU is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
INFU vs HRC Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, HRC has a market cap of 0. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas HRC's P/E ratio is 41.92. In terms of profitability, INFU's ROE is +0.14%, compared to HRC's ROE of +0.14%. Regarding short-term risk, INFU is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HRC's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
INFU vs ATRS Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ATRS's P/E ratio is 14.95. In terms of profitability, INFU's ROE is +0.14%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, INFU is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
INFU vs IVTY Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas IVTY's P/E ratio is -3.80. In terms of profitability, INFU's ROE is +0.14%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, INFU is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for INFU.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
INFU vs ALOG Comparison July 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 183.9M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, INFU is priced at $9.12 on the AMEX, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 23.97, whereas ALOG's P/E ratio is 40.93. In terms of profitability, INFU's ROE is +0.14%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, INFU is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ALOG's competition here